Business
Spectral's EAA(TM) to be featured at The International Symposium of Intensive Care and Emergency Medicine
Spectral's EAA(TM) to be featured at The International Symposium of Intensive Care and Emergency Medicine.
About this update from Spectral Medical Inc
[{"type":"text","content":"\n\n\n\nTORONTO, March 26 /CNW/ - Spectral today announces the presentation of\npositive data concerning the use of the Endotoxin Activity Assay (EAA(TM)) at\nthe 27th Annual International Symposium of Critical Care and Emergency\nMedicine, March 27-30, Brussels, Belgium.\n\n\nDr John Marshall, Professor of Medicine, and current president of the\nInternational Sepsis Forum will present a plenary lecture entitled\n"Endotoxemia in the Critically Ill".\n\n\n"Spectral's EAA(TM) assay, the only world-wide regulatory approved assay\nfor endotoxin in the blood stream, continues to gain acceptance from the\npresentation of the results of our multiple clinical studies, performed by\nleading critical care doctors," stated Dr. Paul Walker, President and CEO.\n"Increased levels of endotoxin seem to play a significant role in a number of\ndifferent disease processes," continued Dr. Walker.\n\n\nSpectral is a developer of innovative technologies for comprehensive\ndisease management. Spectral provides accurate and timely information to\nclinicians enabling the early initiation of appropriate and targeted therapy.\nCurrent products include Spectral's FDA approved rapid diagnostic for West\nNile Virus (RapidWN(TM)) and its FDA approved rapid diagnostic for sepsis\n(EAA(TM)) as well as a range of other biological reagents. Spectral's common\nshares are listed on The Toronto Stock Exchange under the symbol SDI.\n\n\nInformation in this news release that is not current or historical\nfactual information may constitute forward-looking information within the\nmeaning of securities laws. Implicit in this information, particularly in\nrespect of the future outlook of Spectral and anticipated events or results,\nare assumptions based on beliefs of Spectral's senior management as well as\ninformation currently available to it. While these assumptions were considered\nreasonable by Spectral at the time of preparation, they may prove to be\nincorrect. Readers are cautioned that actual results are subject to a number\nof risks and uncertainties, including the availability of funds and resources\nto pursue R&D projects, the successful and timely completion of clinical\nstudies, the ability of Spectral to take advantage of business opportunities\nin the biomedical industry, the granting of necessary approvals by regulatory\n...